

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

INSIDE INFORMATION

LICENSE AGREEMENT WITH GSK

This announcement is made by Hansoh Pharmaceutical Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the inside information provision (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on October 20, 2023 (after trading hours), Shanghai Hansoh BioMedical Company Limited* (上海翰森生物醫藥科技有限公司) (the “**Licensor**”), a wholly-owned subsidiary of the Group, entered into a license agreement (the “**License Agreement**”) with GlaxoSmithKline Intellectual Property (No.4) Limited (“**Licensee**”), pursuant to which the Licensee shall obtain an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong, Macau, and Taiwan) to develop, manufacture and commercialize HS-20089 (the “**Product**”) subject to the terms and conditions thereof.

The Product is a novel B7-H4 directed antibody-drug conjugate (ADC) with a topoisomerase inhibitor (TOPOi) payload. B7-H4, a transmembrane glycoprotein in the B7 superfamily, has limited expression in normal tissues but is highly expressed in various cancers. The Product is being developed for the treatment of advanced solid tumor in a phase I clinical study in China.

Pursuant to the License Agreement and subject to the terms and conditions thereof, the Licensor will receive an upfront payment of US\$85 million and be eligible to receive milestone payments of up to US\$1.485 billion subject to achievement of relevant milestone events with respect to the Product. Upon commercialization of the Product, the Licensee will also pay tiered royalties based on global net sales derived from the territory outside of the Chinese Mainland, Hong Kong, Macau, and Taiwan.

The Licensee is a wholly-owned subsidiary of GSK plc (GSK), which is a global biopharma company headquartered in London, UK.

To the best knowledge and belief of the Company, the Licensee is independent of, and is not connected with, the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). The transactions contemplated under the License Agreement do not constitute any notifiable transactions or connected transactions of the Company under the Listing Rules.

The License Agreement is subject to applicable regulatory agency clearances, including under the Hart-Scott-Rodino Antitrust Improvements Act in the US. The shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, October 20, 2023

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Ms. Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.

* *For identification purposes only*